Arbutus Biopharma Corporation et al v. Moderna, Inc. et al
Case Number:
1:22-cv-00252
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 03, 2026
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight
Moderna announced Tuesday that it will pay $950 million to resolve global patent litigation brought by Arbutus and Genevant Sciences over Moderna's COVID-19 vaccines, with no future royalties, but the company could pay as much as $2.25 billion if it loses an appeal at the Federal Circuit.
-
February 25, 2026
Moderna's Damages Expert Limited In March Patent Trial
Moderna's damages expert was blocked from offering testimony about what a reasonable royalty would be in a suit alleging its COVID-19 vaccine infringed a rival's patents, after a federal judge found that part of the testimony wasn't reliable.
-
February 17, 2026
Judge Trims Moderna's Defenses In COVID Patent Suit
A federal judge sitting in Delaware on Tuesday ruled that Moderna could not use obviousness to defend itself from patent claims brought by a rival vaccine developer since it already used that as a defense in related Patent Trial and Review Board proceedings, saying that Moderna had offered expert opinions to support a defense that the patents don't sufficiently teach about the claimed invention.
-
February 02, 2026
'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit
Moderna Inc. will have to face most of a rival mRNA vaccine developer's $5 billion patent suit over the company's COVID-19 vaccines at a trial in Delaware, a federal judge ruled on Monday, invoking "Star Trek" in a summary judgment order that left issues like patent invalidity up to the jury.
-
August 20, 2025
Feds Lose Bid To Seal In Vax Patent Case Against Moderna
The U.S. government has failed to show why names and contact information of certain U.S. Department of the Army employees should be hidden in an mRNA vaccine developer's $5 billion patent suit over Moderna's COVID-19 vaccines, a federal judge has found.
-
August 04, 2025
Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case
Moderna has urged a Delaware federal judge to clear it in a rival mRNA vaccine developer's $5 billion patent suit over the company's COVID-19 vaccines, saying it is shielded because it made them for the federal government.
-
May 20, 2025
Moderna Says Order To Narrow Vax IP Case Should Stay
Moderna has said that a federal judge should ignore a rival mRNA developer's request to rethink his decision limiting issues in a patent suit over the company's COVID-19 vaccines, saying the rival is trying to make new arguments too late.
-
March 04, 2025
Moderna Faces MRNA Vax Patent Suits In Canada And Beyond
Pennsylvania drug developer Arbutus Biopharma and Genevant Sciences have taken their COVID-19 vaccine litigation against Moderna worldwide, suing the pharmaceutical company in courts in Canada, Japan and Switzerland, along with the Unified Patent Court, alleging infringement.
-
August 20, 2024
Vax Patent Battles Heat Up As Attention On Pandemic Wanes
It's been over four years since clinical trials began for COVID-19 vaccines, and while the shots have helped the pandemic recede, the lucrative technology has spurred numerous patent suits, many of which are still in the early stages. Here's a look at some of the key cases in the U.S.
-
March 10, 2023
Judge Not Convinced By DOJ's 'Say-So' In Vax IP Row
Deciding that it wasn't going to be immediately swayed by "the government's say-so," a Delaware federal court on Friday quickly turned down the Biden administration's efforts to subsume liability for part of a billion-dollar patent dispute over the ownership of the mRNA platform used in Moderna's COVID-19 vaccines.